Articles by Sarah O'Neill, PharmD
Practical Considerations of T-Cell Engagers in the Management of Relapsed/Refractory Multiple Myeloma
ByMatthew M. Lei, PharmD, BCOP,Jack Malespini, PharmD, BCOP,Erica Tavares, PharmD, BCPS, BCOP,Sarah O'Neill, PharmD,Diana Cirstea, MD,E. Bridget Kim, PharmD, BCPS, BCOP Integration of these agents requires supportive care considerations for cytokine release syndrome, neurotoxicity, infection, and antigen-specific toxicities to ensure optimal care of patients with multiple myeloma receiving T-cell–engaging therapies.
